GRI Bio expects cash to fund operations into Q3 of 2024

As of March 31, 2024, the Company had cash and cash equivalents of approximately $4.1 million. Based on the Company’s current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the third quarter of 2024. “We continue to execute on both the clinical and corporate fronts. Our team is working diligently to drive our Phase 2a biomarker study in IPF toward interim data readout which we believe will provide valuable insight for our development program moving forward,” commented Marc Hertz, PhD, Chief Executive Officer of GRI Bio. “On the corporate side, we continue to bolster our patent estate as well as actively engage with and present at scientific meetings which we believe underscore the potential of GRI-0621. We are committed to building a growing body of data and believe we are positioned to unlock significant value in 2024.”